Literature DB >> 10629022

Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.

G Bonfiglio1, C Cascone, C Azzarelli, V Cafiso, F Marchetti, S Stefani.   

Abstract

The in vitro activity of levofloxacin and eight other antimicrobial agents against 60 clinical isolates of Stenotrophomonas maltophilia was determined by an agar dilution method using 10(4) and 10(6) cfu/spot inocula. At the lower inoculum, 85.0% of the isolates were susceptible to levofloxacin but only 58.3% were susceptible to ofloxacin; at the higher inoculum, 78.3% were susceptible to levofloxacin and 36.7% to ofloxacin. In time-kill studies, levofloxacin exerted bactericidal activity within 4 h. With ofloxacin and ciprofloxacin bacterial regrowth was observed after 8 h. Levofloxacin may represent an alternative drug in the treatment of infections caused by S. maltophilia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629022     DOI: 10.1093/jac/45.1.115

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.

Authors:  M L Cohn; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

Authors:  Sun Young Cho; Cheol-In Kang; Jungok Kim; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.

Authors:  Iris H Chen; James M Kidd; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

4.  Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.

Authors:  Sadia H Sarzynski; Sarah Warner; Junfeng Sun; Roland Matsouaka; John P Dekker; Ahmed Babiker; Willy Li; Yi Ling Lai; Robert L Danner; Vance G Fowler; Sameer S Kadri
Journal:  Open Forum Infect Dis       Date:  2022-01-17       Impact factor: 3.835

Review 5.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

6.  Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bacteremia.

Authors:  Siripen Kanchanasuwan; Jakkapan Rongmuang; Pisud Siripaitoon; Narongdet Kositpantawong; Boonsri Charoenmak; Thanaporn Hortiwakul; Ozioma Forstinus Nwabor; Sarunyou Chusri
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

7.  Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.

Authors:  Giovanni Pietro Gesu; Federico Marchetti; Laura Piccoli; Annalisa Cavallero
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.

Authors:  Yu Lin Wang; Marco R Scipione; Yanina Dubrovskaya; John Papadopoulos
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

9.  Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients.

Authors:  K E N Milne; I M Gould
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 10.  New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies.

Authors:  Sara Lo Menzo; Giulia la Martire; Giancarlo Ceccarelli; Mario Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.